Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Esperion Therapeutics's Enterprise Value is $915.9 Mil.
Esperion Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-18.2 Mil. Therefore, Esperion Therapeutics's EV-to-OCF for today is -50.36.
The historical rank and industry rank for Esperion Therapeutics's EV-to-OCF or its related term are showing as below:
ESPR'
s EV-to-OCF Range Over the Past 10 Years
Min: -91.89 Med: -6.73 Max: -0.5
Current: -50.36
During the past 13 years, the highest EV-to-OCF of Esperion Therapeutics was -0.50. The lowest was -91.89. And the median was -6.73.
ESPR's EV-to-OCF is ranked better than 93.95% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs ESPR: -50.36
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Esperion Therapeutics's PE Ratio (TTM) for today is calculated as:
Esperion Therapeutics's share price for today is $3.18.
Esperion Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's EV-to-OCF falls into.
Esperion Therapeutics's current Enterprise Value is $915.9 Mil.
Esperion Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (ESPR) has a EV-to-OCF of -50.36 as of Aug. 04, 2026. According to the industry distribution chart, Esperion Therapeutics ranks #61 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Esperion Therapeutics' EV-to-OCF too high?
Esperion Therapeutics' current EV-to-OCF is -50.36. Based on the distribution chart, Esperion Therapeutics ranks #61 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' EV-to-OCF compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #61 out of 1008 companies for EV-to-OCF. This places Esperion Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current EV-to-OCF is -50.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current EV-to-OCF is -50.36. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current EV-to-OCF is -50.36 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
EV-to-OCF: -50.36
GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score
Get the complete analysis for ESPR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
